Key result
Patients with the lowest quartile of stimulated t-PA release had the highest rate of adverse cardiovascular events over 42 months (P=0.01).
Why the study?
Does endothelial fibrinolytic capacity predict future adverse cardiovascular events in patients with stable coronary heart disease?
Cohort (n=98)
Does endothelial fibrinolytic capacity predict future adverse cardiovascular events in patients with stable coronary heart disease?
p-value: p=0.01
Endothelial fibrinolytic capacity, measured by stimulated t-PA release, is a powerful predictor of future adverse cardiovascular events in patients with stable coronary heart disease.
No takes yet. Share an insight, caveat, or question.
May support t-PA release as prognostic marker in stable CHD; leaves open incremental value beyond standard risk models.
Robinson et al. (2007) conducted a cohort in stable coronary heart disease (n=98). Endothelial fibrinolytic capacity (stimulated t-PA release) vs. Higher fibrinolytic capacity was evaluated on Cardiovascular events (cardiovascular death, myocardial infarction, ischemic stroke, and emergency hospitalization for unstable angina) (p=0.01). Patients with the lowest quartile of stimulated t-PA release had the highest rate of adverse cardiovascular events over 42 months (P=0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: